Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Fedovapagon with Itraconazole or Rifampicin
NCT02440841Phase 1Completed
- Sponsor
- Vantia Therapeutics
- Start
- May 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fedovapagon in nocturia (2 arms), sponsored by Vantia Therapeutics. Primary endpoint: Plasma fedovapagon concentration in presence and absence of co-administered itraconazole or rifampicin. Started May 2015; status: completed.
02
Drugs
fedovapagon
03
Conditions
nocturia
Beyond the preview
Go deeper on NCT02440841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02440841.